4 results on '"Soranna, D"'
Search Results
2. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol
- Author
-
George L. Bakris, Moo Yong Rhee, Richard J McManus, Konstantinos Tsioufis, Kushal Madan, Juan Eugenio Ochoa, Franco Cecchi, Paolo Palatini, Enrico Agabiti-Rosei, Davide Soranna, Paulina Wijnmaalen, Josep Redon, Alberto Zanchetti, Antonella Zambon, Roland E. Schmieder, Pietro Amedeo Modesti, Thomas Kahan, Sabine Perl, Alejandro de la Sierra, Maria Dorobantu, Thays Faria, Mónica Doménech, Bojan Jelaković, Giuseppe Mancia, Jeong Bae Park, Franco Veglio, Ramiro A. Sanchez, Gabriel Waisman, Enrique Rodilla Sala, Giovanna Branzi, Stefano Omboni, Dario Pellegrini, Alexandra Konradi, Yuqing Zhang, Maria Grazia Valsecchi, Nanfang Li, Yong Huo, Ji-Guang Wang, Marzena Chrostowska, Cristian Podoleanu, Nicolas Federico Renna, Stéphane Laurent, Gianfranco Parati, Giacomo Pucci, Milos Stojanovic, José A. Octavio, George S. Stergiou, Grzegorz Bilo, UCH. Departamento de Medicina (Extinguido), Producción Científica UCH 2018, UCH. Departamento de Medicina y Cirugía, Parati, G, Agabiti-Rosei, E, Bakris, G, Bilo, G, Branzi, G, Cecchi, F, Chrostowska, M, De la Sierra, A, Domenech, M, Dorobantu, M, Faria, T, Huo, Y, Jelaković, B, Kahan, T, Konradi, A, Laurent, S, Li, N, Madan, K, Mancia, G, Mcmanus, R, Modesti, P, Ochoa, J, Octavio, J, Omboni, S, Palatini, P, Park, J, Pellegrini, D, Perl, S, Podoleanu, C, Pucci, G, Redon, J, Renna, N, Rhee, M, Rodilla Sala, E, Sanchez, R, Schmieder, R, Soranna, D, Stergiou, G, Stojanovic, M, Tsioufis, K, Valsecchi, M, Veglio, F, Waisman, G, Wang, J, Wijnmaalen, P, Zambon, A, Zanchetti, A, and Zhang, Y
- Subjects
HYPERTENSION MANAGEMENT ,Hipertensión ,masked uncontrolled hypertension ,Enfermedades cardiovasculares - Pacientes - Factores de riesgo ,office blood pressure ,MASKED UNCONTROLLED HYPERTENSION ,Medicina Clínica ,Cardiovascular Medicine ,030204 cardiovascular system & hematology ,AMBULATORY BLOOD PRESSURE MONITORING ,law.invention ,0302 clinical medicine ,Clinical trials ,Randomized controlled trial ,law ,Blood Pressure Monitoring ,Masked Hypertension ,purl.org/becyt/ford/3.2 [https] ,Protocol ,Multicenter Studies as Topic ,030212 general & internal medicine ,Cardiovascular system - Diseases - Patients - Risk factors ,Blood pressure ,OFFICE BLOOD PRESSURE ,Randomized Controlled Trials as Topic ,Sistemas Cardíaco y Cardiovascular ,General Medicine ,Blood Pressure Monitoring, Ambulatory ,3. Good health ,Cor Malalties ,Echocardiography ,Ambulatory ,Hypertension ,purl.org/becyt/ford/3 [https] ,Hipertensió ,ambulatory blood pressure monitoring ,hypertension ,hypertension management ,treated hypertensive patients ,TREATED HYPERTENSIVE PATIENTS ,medicine.medical_specialty ,Ambulatory blood pressure ,CIENCIAS MÉDICAS Y DE LA SALUD ,Heart Ventricles ,treated hypertensive patient ,Pressió sanguínia ,03 medical and health sciences ,medicine ,Albuminuria ,Humans ,Antihypertensive Agents ,Protocol (science) ,business.industry ,Consolidated Standards of Reporting Trials ,Presión sanguínea ,Good clinical practice ,Emergency medicine ,business ,Declaration of Helsinki ,Assaigs clínics - Abstract
Introduction Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. Methods and analysis MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hypertensive patients from about 40 secondary care clinical centres worldwide will be included -upon confirming presence of MUCH (repeated on treatment OBP
- Published
- 2018
3. Do patterns of mental healthcare predict treatment failure in young people with schizophrenia? Evidence from an Italian population-based cohort study
- Author
-
Davide Soranna, Giovanni Corrao, Caterina Viganò, Luca Merlino, Antonio Lora, Emiliano Monzani, Corrao, G, Soranna, D, Merlino, L, Monzani, E, Viganò, C, and Lora, A
- Subjects
Adult ,Male ,Mental Health Services ,medicine.medical_specialty ,Time Factors ,Adolescent ,Medication Adherence ,Cohort Studies ,Young Adult ,Epidemiology ,Medicine ,Humans ,Treatment Failure ,Young adult ,Psychiatry ,Proportional Hazards Models ,business.industry ,Proportional hazards model ,Medicine (all) ,Research ,Attendance ,General Medicine ,medicine.disease ,Mental health ,Mental Health ,Italy ,Schizophrenia ,Cohort ,Female ,business ,Cohort study ,Antipsychotic Agents - Abstract
Objective Little is known about the practice of predicting community-based care effectiveness of patients affected by schizophrenic disorders. We assessed predictors of treatment failure in a large sample of young people affected by schizophrenia. Methods A cohort of 556 patients aged 18–35 years who were originally diagnosed with schizophrenia during 2005–2009 in a Mental Health Service (MHS) of the Italian Lombardy Region was identified. Intensity of mental healthcare received during the first year after index visit (exposure) was measured by patients’ regularity in MHS attendance and the length of time covered with antipsychotic drug therapy. Patients were followed from index visit until 2012 for identifying hospital admission for mental disorder (outcome). A proportional hazards model was fitted to estimate the HR and 95% CIs for the exposure-outcome association, after adjusting for several covariates. A set of sensitivity analyses were performed in order to account for sources of systematic uncertainty. Results During follow-up, 144 cohort members experienced the outcome. Compared with patients on low coverage with antipsychotic drugs (≤4 months), those on intermediate (5–8 months) and high (≥9 months) coverage, had HRs (95% CI) of 0.94 (0.64 to 1.40) and 0.69 (0.48 to 0.98), respectively. There was no evidence that regular attendance at the MHS affected the outcome. Conclusions Patients in the early phase of schizophrenia and their families should be cautioned about the possible consequences of poor antipsychotic adherence. Physicians and decision makers should increase their contribution towards improving mental healthcare.
- Published
- 2015
4. MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.
- Author
-
Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Cecchi F, Chrostowska M, De la Sierra A, Domenech M, Dorobantu M, Faria T, Huo Y, Jelaković B, Kahan T, Konradi A, Laurent S, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Octavio JA, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Renna N, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Veglio F, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, and Zhang Y
- Subjects
- Albuminuria diagnosis, Echocardiography, Heart Ventricles diagnostic imaging, Humans, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Antihypertensive Agents therapeutic use, Blood Pressure Monitoring, Ambulatory, Masked Hypertension drug therapy
- Abstract
Introduction: Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM., Methods and Analysis: MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hypertensive patients from about 40 secondary care clinical centres worldwide will be included -upon confirming presence of MUCH (repeated on treatment OBP <140/90 mm Hg, and at least one of the following: daytime ABP ≥135/85 mm Hg; night-time ABP ≥120/70 mm Hg; 24 hour ABP ≥130/80 mm Hg), and will be randomised to a management strategy based on OBPM (group 1) or on ABPM (group 2). Patients in group 1 will have OBP measured at 0, 3, 6, 12, 18, 24, 30, 36, 42 and 48 months and taken as a guide for treatment; ABPM will be performed at randomisation and at 12, 24, 36 and 48 months but will not be used to take treatment decisions. Patients randomised to group 2 will have ABPM performed at randomisation and all scheduled visits as a guide to antihypertensive treatment. The effects of MUCH management strategy based on ABPM or on OBPM on CV and renal intermediate outcomes (changing left ventricular mass and microalbuminuria, coprimary outcomes) at 1 year and on CV events at 4 years and on changes in BP-related variables will be assessed., Ethics and Dissemination: MASTER study protocol has received approval by the ethical review board of Istituto Auxologico Italiano. The procedures set out in this protocol are in accordance with principles of Declaration of Helsinki and Good Clinical Practice guidelines. Results will be published in accordance with the CONSORT statement in a peer-reviewed scientific journal., Trial Registration Number: NCT02804074; Pre-results., Competing Interests: Competing interests: GP: honoraria as lecturer for Pfizer, Daiichi Sankyo, Menarini, Omron Healthcare. EA-R: honoraria and/or support from Menarini, Servier, Recordati,Guidotti,Malesci, Ferrer, DOC gen, Bruno farm. GLB: principal investigator (FIDElio)-Bayer, Steering committee (CREDENCE(Janssen), SONAR (AbbVie)-Consultant for Merck, Relypsa, Vascular Dynamics, Elceyx, Bayer, Janssen, AbbVie. FC: collaboration with Smart Solutions Technologies S.A.; AMICUS; Boston Scientific International S.A . ADS: honoraria as lecturer for Abbott, Daiichi-Sankyo, Lacer, Menarini, and Pfizer. MD: Honoria from Recordati and Servier. TK: Research grants Karolinska Institutet from Amgen, Medtronic, Pfizer, and Record, all outside the presented work. SL: Honoraria for lecturing from Axelife, Daichi-Sankyo, Fukuda-Denshi, Menarini, Novartis, Omron, Servier and Recordati. GM: honoraria aslecturer Actavis, Amgen, Boehringer Ingelheim, CVRx, Daiichi Sankyo, Ferrer, Medtronic, Menarini, Merck, Novartis, Recordati, Sanofi,Servier. RJM: has received BP Monitors forresearch use from Omron. JR: hasbeen paid as lecturer by Daiichi Sankyo, Menarini, BoehringerIngelheim, MSD. MYR: Lecture honoraria from Pfizer,LG Life Sciences, Bayer Korea, Hanmi Pharm. Co., Yuhan Co., Boryung Pharmaceutical Co., Research grant fromBoryung Pharmaceutical Co. and Dong-A Pharmaceutical Co., CJ HealthCare Co. GS: Conductedvalidation studies for various manufacturers; advised manufacturerson device development. JGW: lecture and consulting fees from Bayer, Daiichi-Sankyo, Novartis,Omron, Pfizer, Sanofi, and Servier. AZ: Honoraria from Menarini International., (© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.